Ceftobiprole,a novel fifth-generation cephalosporin,has gained significant attention as an anti-infective therapy because of its broad-spectrum activity against gram-positive and gram-negative bacteria,as well as its ...Ceftobiprole,a novel fifth-generation cephalosporin,has gained significant attention as an anti-infective therapy because of its broad-spectrum activity against gram-positive and gram-negative bacteria,as well as its effectiveness against drug-resistant strains.This review provides a comprehensive overview of the chemical structure,mechanism of action,antibacterial spectrum,and pharmacokinetic/pharmacodynamic(PK/PD)characteristics of ceftobiprole,with a focus on its clinical efficacy and safety.We also explore its potential applications in treating infections such as skin and soft tissue infections,respiratory infections,and bloodstream infections and evaluate its effectiveness against drug-resistant pathogens.By summarizing current research and clinical practices,we aim to offer insights into optimizing clinical use and advancing antimicrobial agent development.展开更多
基金supported by funding from the Noncommunicable Chronic Diseases-National Science and Technology Major Project(grant number:2024ZD0529005)National Natural Science Foundation of China(No.82230080)+1 种基金Guangdong Provincial Clinical Research Center for Laboratory Medicine(No.2023B110008)Clinical Research Project of Nanfang Hospital,Southern Medical University(No.2023CR015).
文摘Ceftobiprole,a novel fifth-generation cephalosporin,has gained significant attention as an anti-infective therapy because of its broad-spectrum activity against gram-positive and gram-negative bacteria,as well as its effectiveness against drug-resistant strains.This review provides a comprehensive overview of the chemical structure,mechanism of action,antibacterial spectrum,and pharmacokinetic/pharmacodynamic(PK/PD)characteristics of ceftobiprole,with a focus on its clinical efficacy and safety.We also explore its potential applications in treating infections such as skin and soft tissue infections,respiratory infections,and bloodstream infections and evaluate its effectiveness against drug-resistant pathogens.By summarizing current research and clinical practices,we aim to offer insights into optimizing clinical use and advancing antimicrobial agent development.
